


Date: June 6, 2002

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Elias J. Lambiris", written over a horizontal line.

Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097



Attorney Docket No.: 6067.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Roggen et al

Confirmation No: 2466

Serial No.: 09/733,485

Group Art Unit: 1645

Filed: December 8, 2000

Examiner: T. Bhatti

For: High Throughput Screening (HTS) Assays

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Box Sequence
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Sir:

Below is a marked-up version of the amendments made in the accompanying amendment.

IN THE SPECIFICATION:

The paragraph on page 59, lines 31 has been amended as follows:

Analysis with Suc-Ala-Ala-Pro-Phe-pNa (SEQ ID NO:4):

RECEIVED
JUN 1 9 2002
TECH CENTER 1600/2900